Loading...
Coverage, strength, recency, conviction and momentum.
No analyses found yet.
Newest calls at the top.
CEO Paul Hudson evaluates the commercial growth figures and R&D pipeline developments despite the decline in share performance. He analyzes the innovation strategy against drug pricing pressures and the impact of AI on cost efficiency.
The speaker evaluates the company's $2.2 billion acquisition and the Dynavax deal, examining the intensity of M&A activity in the neuro space.
CEO Paul Hudson evaluates the commercial growth figures and R&D pipeline developments despite the decline in share performance. He analyzes the innovation strategy against drug pricing pressures and the impact of AI on cost efficiency.
The speaker evaluates the company's $2.2 billion acquisition and the Dynavax deal, examining the intensity of M&A activity in the neuro space.